learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 801 resultslearn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
learn unspecified lectican proteoglycans (nourkrin)
learn nonspecific group of glycoproteins
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Research
5 / 1000+ resultsresearch Functional interrogation of lymphocyte subsets in alopecia areata using single-cell RNA sequencing
CD8+ T cells drive alopecia areata, while regulatory T cells are protective.
research Frontiers in alopecia areata pathobiology research
The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
research Regulatory T Cells in Autoimmune Diseases and their Potential
Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.
research The role of lymphocytes in the development and treatment of alopecia areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Developing human fetal skin demonstrates a unique lymphocyte signature
Fetal skin has unique immune cells different from adult skin.
Community Join
5 / 1000+ resultscommunity Mallia Aesthetics achieves key regulatory steps for novel sCD83-derived ingredient for hair growth
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community My kotoconazole shampoo contain this
The conversation discusses the safety and use of ketoconazole shampoo for hair loss, with mentions of zinc pyrithione and selenium sulfide. Users debate the safety of these ingredients, particularly zinc pyrithione, and share opinions on regulatory differences between Europe and the US.
community HairClone (UK) finally begins offering its Dermal Papilla Cell Hair Multiplication procedure to humans. In Guatemala.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.